851755-56-1Relevant articles and documents
Preparation method of montelukast sodium impurity H
-
Paragraph 0012, (2021/09/15)
The invention discloses a method for preparing montelukast sodium impurity H. To the invention 2 - (2 - (3) S (- (2 -chloro 7 - quinolinyl) -2 - vinyl) phenyl) -hydroxypropyl) benzoate (compound -3 - A) is under the catalysis of triethylamine. The method
Asymmetric Catalysis with Iron-Salen Complexes
Shaw, Subrata,White, James D.
, p. 2768 - 2780 (2016/08/31)
Iron(III)-salen complexes based on a chiral cis-2,5-diaminobicyclo[2.2.2]octane scaffold are used as catalysts for a variety of stereo selective reactions. High enantio- and diastereoselectivities can be achieved with these catalysts in sulfa-Michael conjugate addition to acyclic α,β-unsaturated ketones, in regioselective δ-addition of thiols to acyclic α,β,γ,δ-unsaturated ketones, and in Conia-ene carbocyclization of alkynyl-substituted β-dicarbonyl compounds. The use of these chiral iron-salen complexes as catalysts provides a new method for conducting these three important reactions under environmentally sustainable conditions.
Identification, synthesis and characterization of impurities of Montelukast sodium
Sunil Kumar,Anjaneyulu,Hima Bindu
, p. 4536 - 4546 (2012/02/04)
Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.
